Z 6568

Drug Profile

Z 6568

Latest Information Update: 11 Jun 1999

Price : $50

At a glance

  • Originator Zambon Group SpA
  • Class Anti-ischaemics; Antihypertensives; Ischaemic heart disorder therapies
  • Mechanism of Action Beta-adrenergic receptor antagonists; Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Hypertension; Ischaemic heart disorders

Most Recent Events

  • 11 Jun 1999 Discontinued-Preclinical for Ischaemic heart disorders in Italy (PO)
  • 11 Jun 1999 Discontinued-Preclinical for Hypertension in Italy (PO)
  • 03 Sep 1998 No-Development-Reported for Hypertension in Italy (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top